寒冷的温度通过短暂的受体潜能 ankyrin1 增强了先天的异性呼吸道炎症
Yoichi Dotake1, Takahiro Matsuyama1, Kentaro Machida1
1Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Frontiers in immunology
|December 1, 2025
概括
暴露于冷空气会通过激活气道细胞中的TRPA1通道使喘恶化. 阻断这些通道可以减少冷气引起的呼吸道炎症,为喘恶化提供新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 道生理学 道生理学
背景情况:
- 喘恶化通常是由冷空气引发的,但潜在的细胞和分子机制尚未完全理解.
- 短暂受体潜在的ankyrin1 (TRPA1) 通道与气道的感觉功能和炎症有关.
研究的目的:
- 研究TRPA1通道在冷空气加重的天生的气道炎症中的作用.
- 阐明TRPA1有助于冷气引起的喘恶化机制.
主要方法:
- 我们使用了一种使用papain刺激与冷空气暴露相结合的小鼠模型.
- 研究了野生型和TRPA1淘汰赛小鼠,以及TRPA1.1的药理抑制.
- 人类支气管上皮细胞被用来评估细胞对TRPA1激活的反应.
主要成果:
- 暴露在寒冷空气中显著增加了与帕帕因治疗的野生型小鼠的乙氨基基基,类型-2先天性淋巴细胞和特定细胞因子水平 (IL-5,IL-13,TSLP).
- 这些冷引起的炎症反应在TRPA1淘汰小鼠和接受TRPA1抗剂治疗的小鼠中被废除.
- 人类支气管上皮细胞中的TRPA1激活增强了帕帕因诱导的TSLP产生.
结论:
- 呼吸道上皮细胞中的TRPA1通道是冷空气诱导的氨酸性呼吸道炎症增强的关键调解者.
- TRPA1激活促进TSLP的产生,导致天生的免疫驱动喘恶化.
- 向TRPA1可能为管理感冒引起的喘恶化提供了一种新的治疗策略.
相关概念视频
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Allergic Reactions
31.9K
Overview
31.9K


